Research
Hormonal
The same 12-week program significantly improves metabolic health markers, including insulin resistance (HOMA index), lipid profiles (triglycerides, VLDL), and inflammatory markers (CRP, PINI), independent of the magnitude of weight loss.
Obesity management should target metabolic health, not just weight. This program improves insulin sensitivity, lowers bad fats (triglycerides/VLDL), and reduces inflammation, which are key risk factors for cardiovascular disease and diabetes.
ModerateSupportsMEDIUM confidence
Biological parameters showed substantial improvements in the carbohydrate profile and insulin resistance (HOMA index) and in the lipid profile with lower plasma triglyceride (p < 0.01) and VLDL (p < 0.01) concentrations. Inflammatory parameters (orosomucoid, ultrasensitive C-reactive protein, and PINI indices) were also substantially reduced.
Why this rating
Same limitations as N1 (open-label, industry-funded).
Source
Impact of a Food Rebalancing Program Associated with Plant-Derived Food Supplements on the Biometric, Behavioral, and Biological Parameters of Obese Subjects
Jean‐Jacques Houben et al. · Nutrients · 2023
DOI 10.3390/nu15224780
cohort · n=200
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A 12-week comprehensive obesity management program combining nutritional education, personalized coaching, and plant-derived food supplements (PDFS) significantly reduces body weight, fat mass, and abdominal circumference in obese subjects compared to a control group receiving only medical observation.Moderate
- Personalized coaching within the program significantly improves behavioral parameters, including quality of life, nutritional habits (Nutriscore), and motivation to change (Prochaska Di Clemente Scale), compared to medical observation alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →